Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novogen Limited NVGN

Healthcare Drug Manufacturers - Specialty & Generic
"Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure. It is an emerging oncology-focused biotechnology company that develops anti-cancer drugs."

Recent & Breaking News (NDAQ:NVGN)

A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Consumer Spending Data

Benzinga.com  August 29, 2016

Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer

PR Newswire Asia August 11, 2016

Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

PR Newswire June 14, 2016

Novogen Patent Covering Anisina(TM) Has Proceeded to Grant

PR Newswire Asia June 13, 2016

Novogen Provides Update On Development Of Cantrixil

PR Newswire Asia May 1, 2016

Novogen Receives R&D Tax Incentive Cash Refund

PR Newswire March 16, 2016

Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

PR Newswire February 19, 2016

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

PR Newswire February 5, 2016

Novogen Appoints Dr James Garner as Chief Executive Officer

PR Newswire December 9, 2015

Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial

PR Newswire November 23, 2015

Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia

PR Newswire November 11, 2015

Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina

PR Newswire November 10, 2015

Novogen Applies for Long-term Options Listing

PR Newswire September 29, 2015

Novogen Announces The Outcome Of A Comprehensive Science Review

PR Newswire August 30, 2015

Newly Appointed Acting CEO Outlines Immediate Plans for Novogen

PR Newswire July 29, 2015

Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board

PR Newswire July 21, 2015

Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma

PR Newswire July 16, 2015

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer

PR Newswire July 13, 2015

Novogen Announces the Chairman's Address at the Company's General Meeting

PR Newswire June 23, 2015

Anisina on Track to Enter Clinic in 2016

PR Newswire June 23, 2015